Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2102MR)

This product GTTS-WQ2102MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2102MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14452MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ6879MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ10606MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ15091MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ1220MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ15056MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ7034MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ8000MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW